Peer-reviewed veterinary case report
Use of tranexamic acid in critically ill dogs and cats 2018-2019
By Kelley, Morgan et al.·Published in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)·2022·Department of Emergency and Critical Care, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective analysis of the use of tranexamic acid in critically ill dogs and cats (2018-2019): 266 dogs and 28 cats.
- Species:
- dog
Plain-English summary
A group of critically ill dogs and cats received tranexamic acid (TXA) to help manage bleeding issues related to conditions like cancer and blood disorders. Most of the dogs had diagnoses such as hemangiosarcoma or bleeding problems, while some cats also faced similar issues or injuries. The treatment was generally safe, with only a few mild side effects reported, including hypersalivation and one seizure in a dog. Overall, TXA was found to be effective for these pets, with minimal adverse effects noted during their hospital stay.
People also search for: dog bleeding treatment · cat cancer care · tranexamic acid for pets · why is my dog hypersalivating · cat seizure causes
Abstract
OBJECTIVE: To describe the signalment, dosing, adverse events, and patient diagnosis for dogs and cats admitted to the critical care unit (CCU) receiving tranexamic acid (TXA). DESIGN: Case series from 2018 to 2019. SETTING: Private referral and primary care veterinary hospital. ANIMALS: Two hundred and sixty-six dogs and 28 cats. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Records of dogs and cats admitted to the CCU that received TXA were evaluated. A diagnosis was assigned to each patient based on the International Statistical Classification of Diseases system. "Neoplasia" ([most frequently] hemangiosarcoma) (89/226 [39%]) and "diseases of the blood and blood forming organs" (idiopathic hemoabdomen, pericardial effusion) (78/226 [34%]) were the most common disease processes for which dogs received TXA. In cats, "diseases of the blood and blood forming organs" (idiopathic hemoabdomen) (9/28 [32%]), "neoplasia" (hemangiosarcoma, mast cell tumor, carcinoma) (7/28 [25%]), and "injury, poisoning, or certain other consequences of external causes" (high-rise syndrome) (5/28 [17%]) were most common. One hundred and forty-eight dogs (65%) and 13 cats (46%) underwent an invasive procedure during hospitalization. Thirty percent (70/226) of dogs received a packed RBC (pRBC) transfusion. Administration of TXA before or after pRBC transfusion did not significantly affect median dose of pRBC administered (P = 0.808). The median IV dose of TXA was similar for dogs and cats at 10 mg/kg. One cat received a 10 times overdose of TXA and did not suffer any appreciable adverse effects. Adverse events were reported in 1.7% (4/226) of dogs including hypersalivation (3/226) and seizure (1/226) in a dog that received a cumulative dose of 280 mg/kg of TXA. Hypersalivation was the only adverse event reported in 3% (1/28) of cats. CONCLUSION: TXA is primarily utilized in critically ill dogs and cats diagnosed with neoplasia, bleeding disorders, and trauma at this institution. Adverse events were infrequent and largely mild.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36047972/